Ranbaxy Laboratories’ German subsidiary - Basics Gmbh in Leverkusen, has launched Atorvastatin basics (10/20/40/80 mg), a generic version of the cholesterol lowering drug Sortis, in the German market.
The company, pursuant to a settlement agreement with Pfizer, has obtained the rights to an early entry of Atorvastatin in the German market. Pfizer’s patent for Sortis expires in Germany on May 7, 2012. Further, Basics’ affiliates in Germany, Daiichi Sankyo Deutschland Gmbh, are expected to assist the company in the launch.
Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: